These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 21904784)

  • 1. Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
    Tsuji S; Miyoshi H; Tomita T; Nakase T; Hamada M; Oomae T; Tsumoto C; Hirata Y; Iguchi M; Edogawa S; Kawai H; Yoshikawa H
    Mod Rheumatol; 2012 Jun; 22(3):353-62. PubMed ID: 21904784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
    Tsuji S; Tomita T; Nakase T; Hamada M; Kawai H; Yoshikawa H
    Int J Rheum Dis; 2014 Jan; 17(1):44-9. PubMed ID: 24472266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
    Inoue T; Iijima H; Arimitsu J; Hagihara K; Kawai S; Shiraishi E; Hiyama S; Mukai A; Shinzaki S; Nishida T; Ogata A; Tsujii M; Takehara T
    Digestion; 2014; 89(2):124-32. PubMed ID: 24526219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
    Sakamoto C; Kawai T; Nakamura S; Sugioka T; Tabira J
    Aliment Pharmacol Ther; 2013 Feb; 37(3):346-54. PubMed ID: 23216412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
    Batu OS; Erol K
    Inflammopharmacology; 2007 Dec; 15(6):260-5. PubMed ID: 18236017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group.
    Hasegawa M; Horiki N; Tanaka K; Wakabayashi H; Tano S; Katsurahara M; Uchida A; Takei Y; Sudo A
    Mod Rheumatol; 2013 Nov; 23(6):1172-8. PubMed ID: 23306427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.
    Cryer B; Li C; Simon LS; Singh G; Stillman MJ; Berger MF
    Am J Gastroenterol; 2013 Mar; 108(3):392-400. PubMed ID: 23399552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
    Emery P; Zeidler H; Kvien TK; Guslandi M; Naudin R; Stead H; Verburg KM; Isakson PC; Hubbard RC; Geis GS
    Lancet; 1999 Dec 18-25; 354(9196):2106-11. PubMed ID: 10609815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study.
    Kobata Y; Yajima H; Yamao J; Tanaka Y; Fukui H; Takakura Y
    Mod Rheumatol; 2009; 19(6):629-36. PubMed ID: 19728013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs.
    Cheatum DE; Arvanitakis C; Gumpel M; Stead H; Geis GS
    Clin Ther; 1999 Jun; 21(6):992-1003. PubMed ID: 10440623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C; Soen S
    Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
    Simon LS; Lanza FL; Lipsky PE; Hubbard RC; Talwalker S; Schwartz BD; Isakson PC; Geis GS
    Arthritis Rheum; 1998 Sep; 41(9):1591-602. PubMed ID: 9751091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.